FeesSafety
Pluang+

SEC approves listing of Volatility Shares' 3x Bitcoin and Ether ETFs, trading pending registration clearance.

Market News
25 Oct 2026, 12:15 WIB
Crypto Briefing
View Source
Bullish
SEC approves listing of Volatility Shares' 3x Bitcoin and Ether ETFs, trading pending registration clearance.

The SEC has approved the listing of six triple-leveraged ETFs from Volatility Shares on the Cboe BZX Exchange, including 3x Bitcoin and 3x Ether ETFs. This marks the first US regulatory approval for crypto products with such high leverage. However, trading cannot begin until the SEC clears the funds' registration statements, with no set timeline for this review. These ETFs aim to triple the daily performance of Bitcoin and Ether futures, offering active traders amplified exposure without managing margin directly, but they are designed for short-term holding due to volatility decay risks.

The SEC's approval of Volatility Shares' 3x Bitcoin and Ether ETFs provides context for crypto market activity. For readers following major cryptocurrencies on Pluang, here is a market snapshot as of Oct 25, 2026 16:21 WIB: out of 50 major cryptocurrencies, only 6 rose while 41 fell. Among notable movers, ENJ (Enjin Coin) dropped 4.98% to Rp442 with 100% sell order activity, contrasting with ONE (Harmony) which fell 5.03% to Rp23 but had a majority buy order activity at 63%. KSM (Kusama) declined 4.83% to Rp67,860 with 87% sell orders, showing varied investor sentiment across assets.

More News

XRP may drop to $0.50 by end-2026 with a 12% chance amid market sell-off and weak support.

XRP may drop to $0.50 by end-2026 with a 12% chance amid market sell-off and weak support.

XRP faces a potential significant correction before the end of 2026, with AI model ChatGPT assigning a 12% probability that the price could crash to $0.50 by December 31. The cryptocurrency recently fell below the key $1 support level amid broader ma...

Market News
Bearish
5 hours ago
ArriVent BioPharma upgraded to Hold after Phase 3 failure but shows potential in early cancer data and strong cash position.

ArriVent BioPharma upgraded to Hold after Phase 3 failure but shows potential in early cancer data and strong cash position.

ArriVent BioPharma was downgraded to Strong Sell after firmonertinib failed its Phase 3 trial, causing shares to drop further. However, new early colorectal cancer data for ARR-217 shows a 44.8% response rate, suggesting some pipeline potential. The ...

Analyst Insights
Neutral
5 hours ago
Crypto selloff cuts XRP 33%, Ethereum 30%, Solana 31%, Bitcoin 24% since Nov 4, raising questions on market bottom.

Crypto selloff cuts XRP 33%, Ethereum 30%, Solana 31%, Bitcoin 24% since Nov 4, raising questions on market bottom.

Since November 4, a crypto market selloff has driven significant losses across major assets: XRP fell 33.07%, Ethereum 30.02%, Solana 30.99%, and Bitcoin 23.61%. XRP experienced the steepest decline, while Bitcoin showed relative resilience. Analyst ...

Bearish
5 hours ago
Binance's Ethereum reserves hit a 5-year low amid market selloff and ongoing withdrawals.

Binance's Ethereum reserves hit a 5-year low amid market selloff and ongoing withdrawals.

Binance's Ethereum reserves have dropped to about 2.9 million ETH, the lowest level since 2021, reflecting a nearly 42% decline since mid-2025 amid a prolonged price correction and market selloff. This decline coincides with continued net outflows fr...

Market News
Bearish
5 hours ago
Crypto analyst sets XRP price target between $5 and $8, calling current levels a 'Sweet Spot'.

Crypto analyst sets XRP price target between $5 and $8, calling current levels a 'Sweet Spot'.

Crypto analyst ChartNerd reiterated a price target for XRP between $5 and $8, describing the current price range as a 'Sweet Spot' for potential gains. The analyst emphasized that this opportunity may not last long but did not specify a timeline for ...

Analyst Insights
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App